EUVIMEDEUVIMED entdecken
Crossref

Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion

Yumeng Zhang, Lynn Nguyen, Chuanyi M Lu, Endi Wang, Marietya I S Lauw, Somedeb Ball, Ning Dong, Lynn Moscinski, Onyee Chan, Seongseok Yun, David Sallman, Lubomir Sokol und 7 weitere

Clinical Lymphoma Myeloma and Leukemia · 2023-03 · 23 (3) · e150-e163

DOI: 10.1016/j.clml.2022.12.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023-03. Verfasst von Yumeng Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Morsani College of Medicine, University of South Florida, Tampa, FL; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Lymphoma, Eosinophilia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Moffitt Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusion (MLN-TK) is an entity encompassed of a heterogeneous group of rare hematopoietic neoplasms that are driven by gene fusion involving PDGDRA/B, FGFR1, JAK2, FLT3 or ETV6::ABL1. Though patients presenting with chronic phase MLN-TK with PDGFRA fusion display a favorable outcome in response to upfront TK inhibitor (TKI) therapy, the outcomes of MLNs driven by other TK fusions are not well described. In this study, we aimed to critically analyze the treatment outcomes of patients with MLN-TK, focusing on the role of upfront TKIs in both chronic- and blast-phase diseases. METHODS: The retrospective study included patients with confirmed MLN-TK from 3 centers and assessed demographic and clinical variables, treatment, and outcomes. RESULTS: Forty-two patients with confirmed MLN-TK [PDGFRA (n = 22), PDGFRB (n = 4), FGFR1(n = 10), JAK2 (n = 2); and FLT3 (n = 3)] were included. Fifteen of 25 (60%) chronic-phased patients received upfront TKI therapy had a long-term remission. Nine of 16 (60%) blast-phase patients with upfront TKIs also achieved complete remission and remained alive at a median follow-up of 20 months. All 3 patients with blast phase disease who received upfront chemotherapy without positive response did not respond to subsequent TKI therapy, emphasizing the importance of initiating TKI therapy early. Upfront TKI therapy was associated with longer overall survival in univariate analyses (HR, 0.054 [95% CI, 0.007-0.42]) and multivariate analyses (HR, 0.03 [95% CI, 0.002-0.47]). CONCLUSION: The outcomes of upfront TKI therapy are excellent for MLN-TK in both chronic and blast phases, regardless of gene abnormalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersLymphomaEosinophiliaHumansTyrosine Kinase InhibitorsRetrospective StudiesBlast CrisisGene FusionProtein Kinase Inhibitors

Stichwörter der Autor:innen

Somatic mutational landscapegene fusionlong-term outcomemyeloid and lymphoid neoplasms with eosinophilia (MLN-TKs)tyrosine kinase inhibitor (TKI)

Substanzen

Tyrosine Kinase InhibitorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Morsani College of Medicine, University of South Florida, Tampa, FL; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Department of Pathology, James A. Haley Veterans' Hospital, Tampa, FL.
  • Department of Laboratory Medicine, University of California, San Francisco, CA.
  • Department of Pathology, Duke University School of Medicine, Durham, NC.
  • Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Department of Hematologic Malignancies, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Förderung

  • Moffitt Cancer Center

Zitieren

APA

Zhang, Y., Nguyen, L., Lu, C. M., Wang, E., Lauw, M. I. S., Ball, S., Dong, N., Moscinski, L., Chan, O., Yun, S., Sallman, D., Sokol, L., Shah, B., Knepper, T., Lancet, J., Komrokji, R., Padron, E., Kuykendall, A., & Zhang, L. (2023). Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. Clinical Lymphoma Myeloma and Leukemia, 23(3), e150-e163. https://doi.org/10.1016/j.clml.2022.12.008

Vancouver

Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, et al. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. Clinical Lymphoma Myeloma and Leukemia. 2023;23(3):e150-e163. doi:10.1016/j.clml.2022.12.008

BibTeX
@article{Zhang2023,
  author = {Zhang, Yumeng and Nguyen, Lynn and Lu, Chuanyi M and Wang, Endi and Lauw, Marietya I S and Ball, Somedeb and Dong, Ning and Moscinski, Lynn and Chan, Onyee and Yun, Seongseok and Sallman, David and Sokol, Lubomir and Shah, Bijal and Knepper, Todd and Lancet, Jeffery and Komrokji, Rami and Padron, Eric and Kuykendall, Andrew and Zhang, Ling},
  title = {Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2023},
  volume = {23},
  number = {3},
  pages = {e150--e163},
  doi = {10.1016/j.clml.2022.12.008}
}
Kostenlos starten →